Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update Gossamer Bio (Nasdaq: GOSS) reported Q4 and full-year 2025 results, provided a corporate update, and outlined next steps after PROSERA Phase 3 topline data.Key points: PROSERA narrowly missed its prespecified alpha at Week 24; prespecified higher‑risk and CTD‑PAH subgroups showed larger 6MWD gains. Enrollment in the PH‑ILD SERANATA study is paused. Year‑end cash and marketable securities were $136.9 million, funding operations into Q1 2027.

#GOSS Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/GOSS/gossamer-bio-a...

Gossamer Bio Faces Major Setback After Phase 3 PROSERA Trial Results Gossamer Bio's Phase 3 PROSERA trial results for seralutinib disappoint investors, leading to a significant drop in stock value. Insights into the implications are examined.

Gossamer Bio Faces Major Setback After Phase 3 PROSERA Trial Results #USA #New_York #Gossamer_Bio #GOSS #seralutinib

📢 Stocks Trending NOW: #NVO #LLY #VNDA #NOVO-B.CO #DPZ #ACLX #IBRX #GOSS #D #TIRX

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CLSK 74% OTM
2. #GOSS 55% OTM
3. #MSTR 54% OTM
4. #ATOM 44% OTM
5. #NIO 41% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CLSK, #GOSS, #MSTR, #ATOM, #NIO

#OptionFlow #OptionsTrading #Trading

Whats your favourite way to study?

I like studying early morning when its still dark!

#studysky #edusky #GOSS #GirlsOnlyStudySpace #WomenInSTEM

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CIFR, #NVTS, #QURE, #STX, #GOSS

#OptionFlow #OptionsTrading #Trading

chat don’t tell me i already know it all but jumpscare, former bird app lesbian mutual posted bf on social i didn’t see it coming 😳 #goss

MultiSearch Tag Explorer MultiSearch Tag Explorer - Explore tags and search results by aéPiot

Maximize Your SEO Reach with Free Backlinks from aéPiot
#MATT #GOSS
allgraph.ro/advanced-sea...
2025 #AFRICA #CUP OF #NATIONS #KNOCKOUT #STAGE
allgraph.ro/advanced-sea...

#aePiot

blueskystarterpack.com/starter-pack...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GOSS, #PLD, #APH, #AEO, #CSGP

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GOSS 17.4x
2. #PLD 16.2x
3. #APH 14.0x
4. #AEO 7.3x
5. #BMY 5.8x

#OptionFlow #OptionsTrading #Trading

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update Gossamer Bio (NASDAQ: GOSS) reported third-quarter 2025 results and a program update on November 5, 2025. Key corporate facts: cash, cash equivalents and marketable securities of $180.2 million as of September 30, 2025, with management saying this provides runway into 2027. The Phase 3 PROSERA study completed enrollment at 390 PAH patients and topline results are expected in February 2026. The first site was activated for the registrational Phase 3 SERANATA study in PH‑ILD (~480 patients randomized across two doses and placebo). Q3 2025 revenue from Chiesi was $13.3M; net loss was $48.2M (Q3 2024: $30.8M).

#GOSS Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/GOSS/gossamer-bio-a...

Artwork recreating Loss with Garfield characters

Reposting with more Garfield appropriate colors for funsies
#Garfield #ctrl+alt+del #loss.jpg #goss

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital Gossamer Bio (NASDAQ:GOSS) has entered into an option agreement to acquire Respira Therapeutics, a Samsara BioCapital portfolio company. The deal centers around RT234, a first-in-class inhaled vardenafil powder being developed as an as-needed (PRN) treatment for pulmonary hypertension (PH).As part of the agreement, Gossamer will issue 2.5 million shares upfront and an additional 1.5 million shares upon exercising the acquisition option. The deal includes success-based milestone payments and royalties on potential RT234 sales. During the two-year option period, Gossamer will fund CMC development activities for RT234.

#GOSS Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

www.stocktitan.net/news/GOSS/respira-therap...

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension Gossamer Bio, Inc., a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced it has entered into an option agreement to acquire Respira Therapeutics and...

#GOSS Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

www.stocktitan.net/news/GOSS/gossamer-bio-e...